Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679258 | 0.81 | CYP19A1 (0.54) | CYP19A1CYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL23732903 | 0.80 | CYP19A1 (0.53) | CYP19A1CYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL171653 | 0.79 | CA2 (0.61) | CYP1A2KMT2ASIGMAR1 | |
| SCHEMBL23732923 | 0.79 | CYP19A1 (0.51) | CYP19A1CYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL15831217 | 0.78 | CYP19A1 (0.55) | CYP19A1MEN1KMT2AMAPTTAAR1 | |
| SCHEMBL2608953 | 0.77 | MEP1B (0.57) | — | |
| SCHEMBL6562890 | 0.77 | GRIA4 (0.51) | MEN1KMT2A | |
| SCHEMBL748924 | 0.76 | SMN1; SMN2 (0.37) | MEN1KMT2AMAPTRAB9A | |
| SCHEMBL6562896 | 0.76 | GRIA4 (0.57) | — | |
| SCHEMBL23703127 | 0.75 | CYP19A1 (0.51) | CYP19A1MEN1KMT2APKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039493-B2 | Biaryl sulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-2205556-A2 | BIARYL SULFONAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009040289-A2 | BIARYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088459-A1 | NOVEL BIARYL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088459-A1 | NOVEL BIARYL SULFONAMIDE DERIVATIVES | NR1H3, NR1H2, NR1H4 | CYP19A1 171/4885CYP1A2 188/4885CYP2D6 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.